arrow
M

Michele Moschetta

AstraZeneca
H指数:51
被引数:7,087

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

naporafenib (LXH254) 联合或不联合spartalizumab在患有MAPK信号通路改变的晚期实体瘤成年患者中的首次人体研究

2024-01-015
OA
HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models
2023-12-011
PRE
Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability
2023-12-013
PRE
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2023-05-3046
OAAI
A View on Drug Development for Cancer Prevention
2023-04-176
OA
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
2021-04-1624
OAAI
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
2021-03-3011
OA
Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER plus metastatic breast cancer
2020-02-150
PRE
A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+HER2-primary breast cancer
2020-02-152
PRE